Having trouble accessing articles? Reset your cache.

Cephalon, ChemGenex Pharmaceuticals deal

Cephalon will acquire the 72.4% of cancer company ChemGenex it does not already own for about A$159 million ($163 million) in

Read the full 215 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE